Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer

DOI: 10.1016/j.celrep.2025.115603

Bioinformatics & Biostatistics Preclinical Pharmacology

Abstract

Molecular subtypes of small cell lung cancer (SCLC) have been described based on differential expression of the transcription factors (TFs) ASCL1, NEUROD1, and POU2F3 and immune-related genes. We previously reported an additional subtype based on expression of the neurogenic TF ATOH1 within our SCLC circulating tumor cell-derived explant (CDX) model biobank. Here, we show that ATOH1 protein is detected in 7 of 81 preclinical models and 16 of 102 clinical samples of SCLC. In CDX models, ATOH1 directly regulates neurogenesis and differentiation programs, consistent with roles in normal tissues. In ex vivo cultures of ATOH1+ CDXs, ATOH1 is required for cell survival. In vivo, ATOH1 depletion slows tumor growth and suppresses liver metastasis. Our data validate ATOH1 as a bona fide lineage-defining TF of SCLC with cell survival and pro-metastatic functions. Further investigation exploring ATOH1-driven vulnerabilities for targeted treatment with predictive biomarkers is warranted.

Authors

Mitchell Revill

Mitchell Revill

Senior Scientific Officer

Derrick Morgan

Derrick Morgan

Tissue Biomarkers Team Manager

Yitao Chen

Yitao Chen

Senior Bioinformatician

Bethan Davies Williams

Bethan Davies Williams

PhD Student

Kevin Brennan

Kevin Brennan

Lead Bioinformatician

Seva Makeev

Seva Makeev

Team Lead

Karishma Satia

Karishma Satia

Senior Scientific Officer

Melanie Galvin

Melanie Galvin

in vivo Team Manager

Caroline Dive

Caroline Dive

Director

Kathryn Simpson

Kathryn Simpson

Team Lead